BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019;5:1020-7. [PMID: 31145418 DOI: 10.1001/jamaoncol.2019.0892] [Cited by in Crossref: 141] [Cited by in F6Publishing: 133] [Article Influence: 141.0] [Reference Citation Analysis]
Number Citing Articles
1 Turpin A, El Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers (Basel) 2020;12:E3866. [PMID: 33371464 DOI: 10.3390/cancers12123866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
2 Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Oncoimmunology 2021;10:1973710. [PMID: 34595057 DOI: 10.1080/2162402X.2021.1973710] [Reference Citation Analysis]
3 Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
4 Michelakos T, Sekigami Y, Kontos F, Fernández-Del Castillo C, Qadan M, Deshpande V, Ting DT, Clark JW, Weekes CD, Parikh A, Ryan DP, Wo JY, Hong TS, Allen JN, Catalano O, Warshaw AL, Lillemoe KD, Ferrone CR. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg 2021. [PMID: 33501584 DOI: 10.1007/s11605-020-04897-9] [Reference Citation Analysis]
5 Maia A, Wiemann S. Cancer-Associated Fibroblasts: Implications for Cancer Therapy. Cancers (Basel) 2021;13:3526. [PMID: 34298736 DOI: 10.3390/cancers13143526] [Reference Citation Analysis]
6 Liot S, Balas J, Aubert A, Prigent L, Mercier-Gouy P, Verrier B, Bertolino P, Hennino A, Valcourt U, Lambert E. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins. Front Immunol 2021;12:612271. [PMID: 33889150 DOI: 10.3389/fimmu.2021.612271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:128-38. [PMID: 33338442 DOI: 10.1016/S2468-1253(20)30330-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
8 Abyaneh HS, Regenold M, McKee TD, Allen C, Gauthier MA. Towards extracellular matrix normalization for improved treatment of solid tumors. Theranostics 2020;10:1960-80. [PMID: 32042347 DOI: 10.7150/thno.39995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
9 Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 2021;13:987. [PMID: 33673405 DOI: 10.3390/cancers13050987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Liermann J, Shinoto M, Syed M, Debus J, Herfarth K, Naumann P. Carbon ion radiotherapy in pancreatic cancer: A review of clinical data. Radiother Oncol 2020;147:145-50. [PMID: 32416281 DOI: 10.1016/j.radonc.2020.05.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Hank T, Sandini M, Qadan M, Weniger M, Ciprani D, Li A, Ferrone CR, Warshaw AL, Lillemoe KD, Fernández-Del Castillo C. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. Pancreatology 2020;20:125-31. [PMID: 31706821 DOI: 10.1016/j.pan.2019.10.007] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
12 Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog 2020;59:775-82. [PMID: 32166821 DOI: 10.1002/mc.23179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
13 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020;17:487-505. [PMID: 32393771 DOI: 10.1038/s41575-020-0300-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 75.0] [Reference Citation Analysis]
14 Darnell EP, Wang TJ, Lumish MA, Hernandez-Barco YG, Weniger M, Casey BW, Qadan M, Lillemoe KD, Ferrone CR, Fernandez-Del Castillo C, Krishnan K. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Am J Surg 2021;221:134-40. [PMID: 32847686 DOI: 10.1016/j.amjsurg.2020.07.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 2020;20:174-86. [PMID: 31980749 DOI: 10.1038/s41568-019-0238-1] [Cited by in Crossref: 447] [Cited by in F6Publishing: 455] [Article Influence: 447.0] [Reference Citation Analysis]
16 Machairas N, Lang H, Jayant K, Raptis DA, Sotiropoulos GC. Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives. Eur J Surg Oncol 2020;46:740-6. [PMID: 32007379 DOI: 10.1016/j.ejso.2020.01.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
17 Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Deng S, Zhou H. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther 2021;6:218. [PMID: 34108441 DOI: 10.1038/s41392-021-00641-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kokkinos J, Jensen A, Sharbeen G, McCarroll JA, Goldstein D, Haghighi KS, Phillips PA. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Cancers (Basel) 2021;13:2427. [PMID: 34067833 DOI: 10.3390/cancers13102427] [Reference Citation Analysis]
20 Florio R, Veschi S, di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N, Cataldi A, Amoroso R, Cama A, De Lellis L. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. Cancers (Basel) 2019;11:E2042. [PMID: 31861153 DOI: 10.3390/cancers11122042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
21 Qadan M, Fernandez-Del Castillo C. Can Prognosis Be Modified in Pancreatic Cancer? Ann Surg Oncol 2020;27:632-3. [PMID: 31701297 DOI: 10.1245/s10434-019-08052-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, Ito Y, Katayama H, Ueno M, Ikeda M, Sugimori K, Okano N, Shimizu K, Yanagimoto H, Okusaka T, Ozaka M, Todaka A, Nakamori S, Tobimatsu K, Sata N, Kawashima Y, Hosokawa A, Yamaguchi T, Miyakawa H, Hara H, Mizuno N, Ishii H; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG). Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol 2021;51:235-43. [PMID: 33164066 DOI: 10.1093/jjco/hyaa198] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, Tsai S, Ferrone CR, B Fleming J, Chang DT, Crane C, Koong AC, Oar A, Parikh P, Erickson B, Hoffe S, Goodman KA. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. J Clin Oncol 2021;39:3773-7. [PMID: 34623894 DOI: 10.1200/JCO.21.01220] [Reference Citation Analysis]
24 Cai B, Lu Z, Neoptolemos JP, Diener MK, Li M, Yin L, Gao Y, Wei J, Chen J, Guo F, Tu M, Xi C, Wu J, Gao W, Dai C, Jiang K, Büchler MW, Miao Y. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Langenbecks Arch Surg 2021;406:691-701. [PMID: 33507403 DOI: 10.1007/s00423-021-02080-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, Chand AL. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Semin Cancer Biol. 2019;. [PMID: 31711994 DOI: 10.1016/j.semcancer.2019.09.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
26 Hilmi M, Nicolle R, Bousquet C, Neuzillet C. Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. Cancers (Basel) 2020;12:E2969. [PMID: 33066357 DOI: 10.3390/cancers12102969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
27 Ganss R. Tumour vessel remodelling: new opportunities in cancer treatment. Vasc Biol 2020;2:R35-43. [PMID: 32923973 DOI: 10.1530/VB-19-0032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
28 Ham IH, Lee D, Hur H. Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers. Cancers (Basel) 2021;13:1172. [PMID: 33803229 DOI: 10.3390/cancers13051172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Thanikachalam K, Damarla V, Seixas T, Dobrosotskaya I, Wollner I, Kwon D, Winters K, Raoufi M, Li J, Siddiqui F, Khan G. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Am J Clin Oncol 2020;43:435-41. [PMID: 32251119 DOI: 10.1097/COC.0000000000000688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Kwon W, Thomas A, Kluger MD. Irreversible electroporation of locally advanced pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00009-9. [PMID: 33648735 DOI: 10.1053/j.seminoncol.2021.02.004] [Reference Citation Analysis]
31 Lou E, Subramanian S. Changing Oncology Treatment Paradigms in the COVID-19 Pandemic. Clin Colorectal Cancer 2020;19:153-5. [PMID: 32419776 DOI: 10.1016/j.clcc.2020.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Masior Ł, Grąt M. Exploring new pathways in the treatment of hepatocellular cancer. Ann Transl Med 2020;8:980. [PMID: 32953780 DOI: 10.21037/atm-20-3629] [Reference Citation Analysis]
34 Ng TSC, Garlin MA, Weissleder R, Miller MA. Improving nanotherapy delivery and action through image-guided systems pharmacology. Theranostics 2020;10:968-97. [PMID: 31938046 DOI: 10.7150/thno.37215] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
35 He B, Ganss R. Modulation of the Vascular-Immune Environment in Metastatic Cancer. Cancers (Basel) 2021;13:810. [PMID: 33671981 DOI: 10.3390/cancers13040810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Arolt C, Hoffmann F, Nachtsheim L, Wolber P, Guntinas-Lichius O, Buettner R, von Eggeling F, Quaas A, Klußmann JP. Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. Head Neck Pathol 2021. [PMID: 34378164 DOI: 10.1007/s12105-021-01370-0] [Reference Citation Analysis]
37 Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol 2021;28:2246-56. [PMID: 33000372 DOI: 10.1245/s10434-020-09149-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
38 Louault K, Li RR, DeClerck YA. Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. Cancers (Basel) 2020;12:E3108. [PMID: 33114328 DOI: 10.3390/cancers12113108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
39 Shen ZT, Zhou H, Li AM, Ji XQ, Jiang CC, Yuan X, Li B, Zhu XX, Huang GC. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. J Cancer Res Clin Oncol 2020;146:417-28. [PMID: 31667573 DOI: 10.1007/s00432-019-03066-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
40 Kim KS, Wu HG. Who Will Benefit from Charged-Particle Therapy? Cancer Res Treat 2021;53:621-34. [PMID: 34176253 DOI: 10.4143/crt.2021.299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Weissleder R, Pittet MJ. The expanding landscape of inflammatory cells affecting cancer therapy. Nat Biomed Eng 2020;4:489-98. [PMID: 32203281 DOI: 10.1038/s41551-020-0524-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
42 Chen J, Li S, Liu X, Liu S, Xiao C, Zhang Z, Li S, Li Z, Yang X. Transforming growth factor-β blockade modulates tumor mechanical microenvironments for enhanced antitumor efficacy of photodynamic therapy. Nanoscale 2021;13:9989-10001. [PMID: 34076013 DOI: 10.1039/d1nr01552d] [Reference Citation Analysis]
43 Cuomo A, Paudice F, D'Angelo G, Perrotta G, Carannante A, Attanasio U, Iengo M, Fiore F, Tocchetti CG, Mercurio V, Pirozzi F. New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management. Curr Heart Fail Rep 2021;18:191-9. [PMID: 34181210 DOI: 10.1007/s11897-021-00517-y] [Reference Citation Analysis]
44 Zhou Z, Yan Y, Zhang Q, Cheng Y. Melanin-like nanoparticles loaded with an angiotensin antagonist for an improved photothermal cancer therapy. Biomater Sci 2020;8:1658-68. [DOI: 10.1039/c9bm01843c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
45 Cheng L, Liu W, Zhong C, Ni P, Ni S, Wang Q, Zhang Q, Zhang J, Liu J, Xu M, Yao X, Cen X, Wang G, Jiang C, Zhou F. Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy. J Ethnopharmacol 2021;270:113770. [PMID: 33388426 DOI: 10.1016/j.jep.2020.113770] [Reference Citation Analysis]
46 Yanagimoto H, Satoi S, Yamamoto T, Yamaki S, Hirooka S, Kotsuka M, Ryota H, Ishida M, Matsui Y, Sekimoto M. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1428. [PMID: 32486418 DOI: 10.3390/cancers12061428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 He C, Sun S, Zhang Y, Li S. Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. J Inflamm Res 2021;14:4795-807. [PMID: 34584438 DOI: 10.2147/JIR.S331023] [Reference Citation Analysis]
48 Yoo C, Lee SS, Song KB, Jeong JH, Hyung J, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Lee SS, Kim JH, Jin HS, Park JH, Hwang DW, Lee JH, Lee W, Chang HM, Kim KP, Ryoo BY, Kim SC. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. Br J Cancer 2020;123:362-8. [PMID: 32433600 DOI: 10.1038/s41416-020-0867-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
49 Arolt C, Meyer M, Hoffmann F, Wagener-Ryczek S, Schwarz D, Nachtsheim L, Beutner D, Odenthal M, Guntinas-Lichius O, Buettner R, von Eggeling F, Klußmann JP, Quaas A. Expression Profiling of Extracellular Matrix Genes Reveals Global and Entity-Specific Characteristics in Adenoid Cystic, Mucoepidermoid and Salivary Duct Carcinomas. Cancers (Basel) 2020;12:E2466. [PMID: 32878206 DOI: 10.3390/cancers12092466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
50 Liu Y, Zhou J, Li Q, Li L, Jia Y, Geng F, Zhou J, Yin T. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma. Adv Drug Deliv Rev 2021;172:80-103. [PMID: 33705874 DOI: 10.1016/j.addr.2021.02.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Martins Cavaco AC, Dâmaso S, Casimiro S, Costa L. Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer Metastasis Rev 2020;39:603-23. [PMID: 32447477 DOI: 10.1007/s10555-020-09888-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
52 Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol 2021;94:20201397. [PMID: 33684308 DOI: 10.1259/bjr.20201397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL 2nd, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, Jaffee EM, Eshleman J, Szabolcs A, Ryan DP, Ting DT, Wolfgang CL, Burkhart RA. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Ann Surg 2020;272:427-35. [PMID: 32657929 DOI: 10.1097/SLA.0000000000004200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
54 Sekigami Y, Michelakos T, Fernandez-Del Castillo C, Kontos F, Qadan M, Wo JY, Harrison J, Deshpande V, Catalano O, Lillemoe KD, Hong TS, Ferrone CR. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Ann Surg Oncol 2021;28:4592-601. [PMID: 33393047 DOI: 10.1245/s10434-020-09444-z] [Reference Citation Analysis]
55 Martin JD, Miyazaki T, Cabral H. Remodeling tumor microenvironment with nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1730. [PMID: 34124849 DOI: 10.1002/wnan.1730] [Reference Citation Analysis]
56 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 23.0] [Reference Citation Analysis]
57 Dai W, Qiu X, Lu C, Zou Z, Sha H, Kong W, Liu B, Du J. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Front Oncol 2021;11:693386. [PMID: 34722242 DOI: 10.3389/fonc.2021.693386] [Reference Citation Analysis]
58 Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 2020;17:527-40. [PMID: 32398706 DOI: 10.1038/s41571-020-0363-5] [Cited by in Crossref: 82] [Cited by in F6Publishing: 97] [Article Influence: 82.0] [Reference Citation Analysis]
59 Chawla A, Ferrone CR. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Front Oncol 2019;9:1085. [PMID: 31681614 DOI: 10.3389/fonc.2019.01085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
60 He C, Sun S, Huang X, Zhang Y, Lin X, Li S. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. Front Oncol 2020;10:622318. [PMID: 33604301 DOI: 10.3389/fonc.2020.622318] [Reference Citation Analysis]
61 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
62 Chawla A. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. J Surg Oncol 2021;123:1423-31. [PMID: 33831254 DOI: 10.1002/jso.26393] [Reference Citation Analysis]
63 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021; 27(35): 5851-5889 [PMID: 34629806 DOI: 10.3748/wjg.v27.i35.5851] [Reference Citation Analysis]
64 Gelosa P, Castiglioni L, Camera M, Sironi L. Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage? Biochem Pharmacol 2020;177:113895. [PMID: 32145263 DOI: 10.1016/j.bcp.2020.113895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
65 van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol 2019;14:1007-17. [PMID: 31695150 DOI: 10.1038/s41565-019-0567-y] [Cited by in Crossref: 289] [Cited by in F6Publishing: 243] [Article Influence: 144.5] [Reference Citation Analysis]
66 Kleeff J, Ronellenfitsch U, Michalski CW. Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? EClinicalMedicine 2019;17:100222. [PMID: 31891149 DOI: 10.1016/j.eclinm.2019.11.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Cox TR. The matrix in cancer. Nat Rev Cancer 2021;21:217-38. [PMID: 33589810 DOI: 10.1038/s41568-020-00329-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
68 Mehta A, Hwang WL, Weekes C. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Ann Pancreat Cancer 2020;3:3. [PMID: 33294843 DOI: 10.21037/apc-2020-pda-05] [Reference Citation Analysis]
69 Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers (Basel) 2021;13:2053. [PMID: 33922795 DOI: 10.3390/cancers13092053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
70 Hall WA, Erickson B, Crane CH. Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:719-30. [PMID: 34511192 DOI: 10.1016/j.soc.2021.06.009] [Reference Citation Analysis]
71 Perini MV, Dmello RS, Nero TL, Chand AL. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther 2020;211:107527. [PMID: 32173557 DOI: 10.1016/j.pharmthera.2020.107527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
72 Cho WK, Yu JI, Park HC, Lim DH, Kim TH, Chie EK. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. Tumori 2021;107:247-53. [PMID: 32646298 DOI: 10.1177/0300891620937795] [Reference Citation Analysis]
73 Zhou Y, Liao S, You J, Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 2021. [PMID: 34021484 DOI: 10.1007/s13304-021-01089-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Pan Y, Song X, Wang Y, Wei J. Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies. Pharmaceutics 2021;13:1338. [PMID: 34575414 DOI: 10.3390/pharmaceutics13091338] [Reference Citation Analysis]
75 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Reference Citation Analysis]
76 Romero D. From the 2019 ASCO Annual Meeting. Nat Rev Clin Oncol 2019;16:463. [PMID: 31213702 DOI: 10.1038/s41571-019-0245-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Carlos-Escalante JA, de Jesús-Sánchez M, Rivas-Castro A, Pichardo-Rojas PS, Arce C, Wegman-Ostrosky T. The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer. Front Oncol 2021;11:660943. [PMID: 34094953 DOI: 10.3389/fonc.2021.660943] [Reference Citation Analysis]
78 Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, Rossi G, Addari L, Giuliani T, Pollini T, Cavedon C, Salvia R, Milella M, Bassi C, Mazzarotto R. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Clin Oncol (R Coll Radiol). 2021;33:e31-e38. [PMID: 32682686 DOI: 10.1016/j.clon.2020.06.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
79 Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev 2021;101:147-76. [PMID: 32466724 DOI: 10.1152/physrev.00048.2019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 38.0] [Reference Citation Analysis]
80 Mpekris F, Panagi M, Voutouri C, Martin JD, Samuel R, Takahashi S, Gotohda N, Suzuki T, Papageorgis P, Demetriou P, Pierides C, Koumas L, Costeas P, Kojima M, Ishii G, Constantinidou A, Kataoka K, Cabral H, Stylianopoulos T. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Adv Sci (Weinh) 2021;8:2001917. [PMID: 33552852 DOI: 10.1002/advs.202001917] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
81 Yang L, Bai Y, Li Q, Chen J, Liu F, Weng X, Xu F. Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Front Oncol 2021;11:695645. [PMID: 34485131 DOI: 10.3389/fonc.2021.695645] [Reference Citation Analysis]
82 Brown ZJ, Cloyd JM. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. J Surg Oncol. 2021;123:1432-1440. [PMID: 33831253 DOI: 10.1002/jso.26384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci 2019;20:E4504. [PMID: 31514451 DOI: 10.3390/ijms20184504] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 32.0] [Reference Citation Analysis]
84 Franks SJ, Firipis K, Ferreira R, Hannan KM, Williams RJ, Hannan RD, Nisbet DR. Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents. Mater Horiz 2020;7:1996-2010. [DOI: 10.1039/d0mh00398k] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
85 Cuomo A, Pirozzi F, Attanasio U, Franco R, Elia F, De Rosa E, Russo M, Ghigo A, Ameri P, Tocchetti CG, Mercurio V. Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. Curr Oncol Rep 2020;23:7. [PMID: 33263821 DOI: 10.1007/s11912-020-00990-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
86 Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut 2021:gutjnl-2020-322493. [PMID: 33431577 DOI: 10.1136/gutjnl-2020-322493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Reese M, Dhayat SA. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. J Hematol Oncol 2021;14:141. [PMID: 34496946 DOI: 10.1186/s13045-021-01149-4] [Reference Citation Analysis]
88 Yang HH, Liu JW, Lee JH, Harn HJ, Chiou TW. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. Int J Mol Sci 2021;22:8125. [PMID: 34360896 DOI: 10.3390/ijms22158125] [Reference Citation Analysis]
89 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 25.0] [Reference Citation Analysis]
90 Kudo M, Kobayashi T, Gotohda N, Konishi M, Takahashi S, Kobayashi S, Sugimoto M, Okubo S, Martin J, Cabral H, Ishii G, Kojima M. Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer. Pancreas 2020;49:634-41. [PMID: 32433400 DOI: 10.1097/MPA.0000000000001539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Chen J, Ding ZY, Li S, Liu S, Xiao C, Li Z, Zhang BX, Chen XP, Yang X. Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy. Theranostics 2021;11:1345-63. [PMID: 33391538 DOI: 10.7150/thno.51383] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
92 Koh M, Park JH, Yoo C, Yoon SM, Jung J, Ryoo BY, Chang HM, Kim KP, Jeong JH, Kim JH. Radiation therapy for recurrent extrahepatic bile duct cancer. PLoS One 2021;16:e0253285. [PMID: 34133471 DOI: 10.1371/journal.pone.0253285] [Reference Citation Analysis]
93 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Shen Y, Wang X, Lu J, Salfenmoser M, Wirsik NM, Schleussner N, Imle A, Freire Valls A, Radhakrishnan P, Liang J, Wang G, Muley T, Schneider M, Ruiz de Almodovar C, Diz-Muñoz A, Schmidt T. Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer. Cancer Cell 2020;37:800-817.e7. [PMID: 32516590 DOI: 10.1016/j.ccell.2020.05.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 43.0] [Reference Citation Analysis]
95 Siljee S, Pilkington T, Brasch HD, Bockett N, Patel J, Paterson E, Davis PF, Tan ST. Cancer Stem Cells in Head and Neck Metastatic Malignant Melanoma Express Components of the Renin-Angiotensin System. Life (Basel) 2020;10:E268. [PMID: 33147716 DOI: 10.3390/life10110268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
96 Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. Drug Deliv Transl Res 2021. [PMID: 34176099 DOI: 10.1007/s13346-021-01018-0] [Reference Citation Analysis]
97 Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2020;38:1081. [PMID: 32013670 DOI: 10.1200/JCO.19.03141] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 28.0] [Reference Citation Analysis]
98 [DOI: 10.1101/2020.08.25.267336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Mortezaee K. Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. J Biochem Mol Toxicol 2021;35:e22708. [PMID: 33491255 DOI: 10.1002/jbt.22708] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
100 Kim HS, Nakagawa K, Akahori T, Nakamura K, Takagi T, Sho M, Park JS, Yoon DS. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? J Clin Med 2021;10:873. [PMID: 33672686 DOI: 10.3390/jcm10040873] [Reference Citation Analysis]
101 Hauge A, Rofstad EK. Antifibrotic therapy to normalize the tumor microenvironment. J Transl Med 2020;18:207. [PMID: 32434573 DOI: 10.1186/s12967-020-02376-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
102 Gromisch C, Qadan M, Machado MA, Liu K, Colson Y, Grinstaff MW. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Res 2020;80:3179-92. [PMID: 32220831 DOI: 10.1158/0008-5472.CAN-19-2731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
103 De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, Florio R, Grassadonia A, Cama A. Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. Cancers (Basel) 2021;13:3946. [PMID: 34439102 DOI: 10.3390/cancers13163946] [Reference Citation Analysis]
104 Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Alexandra Diaz D, Miller ED, Chen W, Frankel WL, Noonan A, Williams TM. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med 2020;9:4711-23. [PMID: 32415696 DOI: 10.1002/cam4.3075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
105 Veerasubramanian PK, Trinh A, Akhtar N, Liu WF, Downing TL. Biophysical and epigenetic regulation of cancer stemness, invasiveness and immune action. Curr Tissue Microenviron Rep 2020;1:277-300. [PMID: 33817661 DOI: 10.1007/s43152-020-00021-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Tomasello G, Ghidini M, Ghidini A, Trevisan F, Celotti A, Russo A, Gambini D, Indini A, Rijavec E, Bareggi C, Galassi B, Petrelli F. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. Radiother Oncol 2021;164:13-9. [PMID: 34509562 DOI: 10.1016/j.radonc.2021.09.001] [Reference Citation Analysis]
107 Li W, Li S, Chen IX, Liu Y, Ramjiawan RR, Leung CH, Gerweck LE, Fukumura D, Loeffler JS, Jain RK, Duda DG, Huang P. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiat Oncol 2021;16:48. [PMID: 33663521 DOI: 10.1186/s13014-021-01775-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Watt DM, Morton JP. Heterogeneity in Pancreatic Cancer Fibroblasts-TGFβ as a Master Regulator? Cancers (Basel) 2021;13:4984. [PMID: 34638468 DOI: 10.3390/cancers13194984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Reference Citation Analysis]
110 Stefanowicz S, Wlodarczyk W, Frosch S, Zschaeck S, Troost EGC. Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical. Clin Transl Radiat Oncol 2021;27:24-31. [PMID: 33392399 DOI: 10.1016/j.ctro.2020.12.001] [Reference Citation Analysis]
111 Inoue Y, Oba A, Ono Y, Sato T, Ito H, Takahashi Y. Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy-Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers (Basel) 2021;13:1818. [PMID: 33920314 DOI: 10.3390/cancers13081818] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Wadsworth BJ, Cederberg RA, Lee CM, Firmino NS, Franks SE, Pan J, Colpo N, Lin KS, Benard F, Bennewith KL. Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. Cancer Lett 2020;493:31-40. [PMID: 32763272 DOI: 10.1016/j.canlet.2020.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
113 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Stokes WA, Molina E, McDermott JD, Morgan RL, Bickett T, Fakhoury KR, Amini A, Karam SD. Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer. Head Neck 2021. [PMID: 34289190 DOI: 10.1002/hed.26809] [Reference Citation Analysis]
115 Dhaliwal A, Zheng G. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery. Theranostics 2019;9:8091-108. [PMID: 31754383 DOI: 10.7150/thno.37204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
116 Rossi G, Simoni N, Paiella S, Rossi R, Venezia M, Micera R, Malleo G, Salvia R, Giuliani T, Di Gioia A, Auriemma A, Milella M, Guariglia S, Cavedon C, Bassi C, Mazzarotto R. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Front Oncol 2021;11:662205. [PMID: 33959509 DOI: 10.3389/fonc.2021.662205] [Reference Citation Analysis]
117 Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol 2020;17:251-66. [PMID: 32034288 DOI: 10.1038/s41571-019-0308-z] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 125.0] [Reference Citation Analysis]
118 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
119 Yu Y, Zheng P, Chen Y, Wang B, Paul ME, Tao P, Wang D, Li H, Gu B, Gao L, Wang D, Chen H. Advances and challenges of neoadjuvant therapy in pancreatic cancer. Asia Pac J Clin Oncol 2020. [PMID: 33164329 DOI: 10.1111/ajco.13504] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Ward EP, Zeh Iii HJ, Tsai S. Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:657-71. [PMID: 34511188 DOI: 10.1016/j.soc.2021.06.010] [Reference Citation Analysis]
121 Mi P, Miyata K, Kataoka K, Cabral H. Clinical Translation of Self‐Assembled Cancer Nanomedicines. Adv Therap 2021;4:2000159. [DOI: 10.1002/adtp.202000159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
122 Li SS, Klempner SJ, Costantino CL, Parikh A, Clark JW, Wo JY, Hong TS, Mullen JT. Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. Ann Surg Oncol 2021;28:2856-65. [PMID: 33393043 DOI: 10.1245/s10434-020-09248-1] [Reference Citation Analysis]
123 Rudno-Rudzińska J, Kielan W, Guziński M, Płochocki M, Antończyk A, Kulbacka J. New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP) - A pilot preclinical study. Surg Oncol 2021;38:101634. [PMID: 34303953 DOI: 10.1016/j.suronc.2021.101634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Ann Gastroenterol Surg 2020;4:100-8. [PMID: 32258974 DOI: 10.1002/ags3.12311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
125 Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 2021;70:606-17. [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
126 Kozlova N, Grossman JE, Iwanicki MP, Muranen T. The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers. Trends in Pharmacological Sciences 2020;41:183-98. [DOI: 10.1016/j.tips.2020.01.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
127 Munn LL, Nia HT. Mechanosensing tensile solid stresses. Proc Natl Acad Sci U S A 2019;116:21960-2. [PMID: 31619566 DOI: 10.1073/pnas.1916115116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
128 Yoo C, Hwang I, Song TJ, Lee SS, Jeong JH, Park DH, Seo DW, Lee SK, Kim MH, Byun JH, Park JH, Hwang DW, Song KB, Lee JH, Lee W, Chang HM, Kim KP, Kim SC, Ryoo BY. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.Ther Adv Med Oncol. 2020;12:1758835920953294. [PMID: 32983266 DOI: 10.1177/1758835920953294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
129 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Pu N, Yin H, Chen Q, Zhang J, Wu W, Lou W. Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. J Hepatobiliary Pancreat Sci 2021. [PMID: 34514722 DOI: 10.1002/jhbp.1045] [Reference Citation Analysis]
131 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
132 Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen L, Zhou J. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. J Cancer Res Clin Oncol 2021;147:1529-36. [PMID: 33191450 DOI: 10.1007/s00432-020-03442-0] [Reference Citation Analysis]
133 Sofias AM, De Lorenzi F, Peña Q, Azadkhah Shalmani A, Vucur M, Wang JW, Kiessling F, Shi Y, Consolino L, Storm G, Lammers T. Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Adv Drug Deliv Rev 2021;175:113831. [PMID: 34139255 DOI: 10.1016/j.addr.2021.113831] [Reference Citation Analysis]
134 Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science 2020;370:eaaz0868. [PMID: 33122355 DOI: 10.1126/science.aaz0868] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 53.0] [Reference Citation Analysis]
135 Luongo M, Marinelli O, Zeppa L, Aguzzi C, Morelli MB, Amantini C, Frassineti A, di Costanzo M, Fanelli A, Santoni G, Nabissi M. Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel) 2020;12:E2774. [PMID: 32992648 DOI: 10.3390/cancers12102774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Curry DE, Al-Sayed AA, Trites J, Wheelock M, Acott PD, Midgen C, Johnson LB, Bezuhly M. Oral Losartan After Limited Mandibulectomy for Treatment of Desmoid-Type Fibromatosis. Ear Nose Throat J 2021;:145561320987641. [PMID: 33491484 DOI: 10.1177/0145561320987641] [Reference Citation Analysis]
137 Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, Kouchakji E, Rocha F, Carrier E. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open 2020;5:e000668. [PMID: 32817130 DOI: 10.1136/esmoopen-2019-000668] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
138 Ganguly D, Chandra R, Karalis J, Teke M, Aguilera T, Maddipati R, Wachsmann MB, Ghersi D, Siravegna G, Zeh HJ 3rd, Brekken R, Ting DT, Ligorio M. Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. Cancers (Basel) 2020;12:E2652. [PMID: 32957515 DOI: 10.3390/cancers12092652] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
139 Al-Saeedi M, Frank-Moldzio L, Contin P, Mayer P, Loos M, Schmidt T, Schneider M, Müller-Stich BP, Berchtold C, Mehrabi A, Hackert T, Büchler MW, Strobel O. Splenorenal shunt for reconstruction of the gastric and splenic venous drainage during pancreatoduodenectomy with resection of the portal venous confluence. Langenbecks Arch Surg 2021;406:2535-43. [PMID: 34618219 DOI: 10.1007/s00423-021-02318-2] [Reference Citation Analysis]
140 Xu X, Wu Y, Qian X, Wang Y, Wang J, Li J, Li Y, Zhang Z. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy. Adv Healthc Mater 2021;:e2101428. [PMID: 34706400 DOI: 10.1002/adhm.202101428] [Reference Citation Analysis]
141 Heudobler D, Lüke F, Vogelhuber M, Klobuch S, Pukrop T, Herr W, Gerner C, Pantziarka P, Ghibelli L, Reichle A. Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction. Front Oncol 2019;9:1408. [PMID: 31921665 DOI: 10.3389/fonc.2019.01408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
142 Schmocker RK, Wright MJ, Ding D, Beckman MJ, Javed AA, Cameron JL, Lafaro KJ, Burns WR, Weiss MJ, He J, Wolfgang CL, Burkhart RA. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR). Ann Surg Oncol 2021;28:3125-34. [PMID: 33051739 DOI: 10.1245/s10434-020-09201-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
143 Zhang ML, Kem M, Rodrigues C, Sandini M, Ciprani D, Hank T, Kunitoki K, Qadan M, Ferrone C, Lillemoe K, Fernández-Del Castillo C, Mino-Kenudson M. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Histopathology 2020;77:144-55. [PMID: 31965618 DOI: 10.1111/his.14067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]